繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

Supernus Pharmaceuticals Says US FDA Accepts NDA Resubmission for Potential Parkinson's Related Treatment Device

2024-08-19 20:15

08:15 AM EDT, 08/19/2024 (MT Newswires) -- Supernus Pharmaceuticals (SUPN) said Monday that the US Food and Drug Administration had accepted its resubmission of a new drug application for its apomorphine infusion device, which is intended for continuous treatment of motor fluctuations in Parkinson's disease patients.

The company said the agency has set a target Prescription Drug User Fee Act date of Feb. 1.

Shares of Supernus were up 3.4% in recent premarket activity.

Price: 35.73, Change: +1.18, Percent Change: +3.42

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。